Skip to main content
. Author manuscript; available in PMC: 2018 Oct 9.
Published in final edited form as: Exp Hematol. 2014 Apr 2;42(7):536–46.e8. doi: 10.1016/j.exphem.2014.03.006

Figure 4.

Figure 4.

Inhibitors to HDACs, DNMTs, and LSD1 alter globin expression in β-yac ESREs. Error bars represent standard error of a minimum of three independent experiments. (A) Inhibitors to chromatin modifiers induce γ-globin expression in β-yac ESREs. β-yac ESREs were placed in maturation media with either vehicle control (dimethyl sulfoxide), TCP, DB, a combination of TCP and DB (TCP/DB), sodium butyrate, or HU for 24 hours. Then, globin expression was assessed by quantitative PCR. Light grey bars represent HBG1 expression, dark grey bars represent HBG2 expression, and black bars represent HBE expression. A statistically significant increase in gamma globin expression was seen in all treatment conditions. (B) β-yac ESREs treated with TCP, DB, and sodium butyrate express less β-globin from the transgenic human locus than vehicle-treated controls. (C) Data are presented as percent of total human globin. Error bars represent SEM of a minimum of three independent experiments. DB = Decitabine; DMSO = dimethyl sulf-oxide; HBB = β-globin; HBE = hemoglobin E; HBG1 = hemoglobin, Gamma A (γA); HBG2 = hemoglobin, Gamma G (γG).